Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
|Videos|March 11, 2022
Significance of imaging in retinal disease scans
Mohammad Rafieetary, OD, FAAO, shares highlights from his SECO 2022 presentation titled "Image-in that! Scanning for retinal disease."
Advertisement
Mohammad Rafieetary, OD, FAAO, consultative optometric physician at the Charles Retina Institute in Germantown, Tennessee, speaks with Optometry Times®' Alex Delaney-Gesing on highlights from his SECO 2022 presentation titled "Image-in that! Scanning for retinal disease," including why optometrists should be knowledgeable about their diagnoistic devices.
Advertisement
Related to this article
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The untapped partnership between retinal specialists and optometrists in myopia care
2
More magic in Anaheim: Highlights from AAOpt 2026
3
2026 legislative roundup: Scope, vision plans, and Medicare pay
4
From our Editorial Board: Comments from the FDA Advisory Committee meeting on SYD-101
5